Limits...
In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus

Flexing (a), licking (b), and jerking (c) of the injected paw in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups during the second phase (20–45 min, a–c) of FT1, FT2, and FT3. ANOVA showed that BCP and BCP+DHA administration significantly reduced the formalin-induced responses, in particular, during the second phase of FT2 and FT3. Values are means ± SEM. **P < 0.0001 versus FT1; *P < 0.02 versus FT1; ##P < 0.0001 versus OIL, same test; #P < 0.01 versus OIL, same test.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4109702&req=5

fig8: Flexing (a), licking (b), and jerking (c) of the injected paw in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups during the second phase (20–45 min, a–c) of FT1, FT2, and FT3. ANOVA showed that BCP and BCP+DHA administration significantly reduced the formalin-induced responses, in particular, during the second phase of FT2 and FT3. Values are means ± SEM. **P < 0.0001 versus FT1; *P < 0.02 versus FT1; ##P < 0.0001 versus OIL, same test; #P < 0.01 versus OIL, same test.

Mentions: Flexing. Two-way ANOVA revealed a significant effect of Treatment (F2,62 = 12.25; P < 0.001), Test (F2,62 = 18.92; P < 0.001), and the Treatment × Test interaction (F4,62 = 3.63; P < 0.01). As shown in Figure 8(a), this was due to the reduction of formalin-induced flexing in the BCP group in FT2 and FT3 with respect to FT1 (P < 0.001 for both). In the BCP+DHA group, flexing duration was decreased in FT2 and FT3 with respect to FT1 (P < 0.0001 and P < 0.002, resp.) but was lower than in the OIL group only during FT3 (P < 0.002).


In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Flexing (a), licking (b), and jerking (c) of the injected paw in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups during the second phase (20–45 min, a–c) of FT1, FT2, and FT3. ANOVA showed that BCP and BCP+DHA administration significantly reduced the formalin-induced responses, in particular, during the second phase of FT2 and FT3. Values are means ± SEM. **P < 0.0001 versus FT1; *P < 0.02 versus FT1; ##P < 0.0001 versus OIL, same test; #P < 0.01 versus OIL, same test.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4109702&req=5

fig8: Flexing (a), licking (b), and jerking (c) of the injected paw in OIL (white), BCP (light gray), and BCP+DHA (dark gray) groups during the second phase (20–45 min, a–c) of FT1, FT2, and FT3. ANOVA showed that BCP and BCP+DHA administration significantly reduced the formalin-induced responses, in particular, during the second phase of FT2 and FT3. Values are means ± SEM. **P < 0.0001 versus FT1; *P < 0.02 versus FT1; ##P < 0.0001 versus OIL, same test; #P < 0.01 versus OIL, same test.
Mentions: Flexing. Two-way ANOVA revealed a significant effect of Treatment (F2,62 = 12.25; P < 0.001), Test (F2,62 = 18.92; P < 0.001), and the Treatment × Test interaction (F4,62 = 3.63; P < 0.01). As shown in Figure 8(a), this was due to the reduction of formalin-induced flexing in the BCP group in FT2 and FT3 with respect to FT1 (P < 0.001 for both). In the BCP+DHA group, flexing duration was decreased in FT2 and FT3 with respect to FT1 (P < 0.0001 and P < 0.002, resp.) but was lower than in the OIL group only during FT3 (P < 0.002).

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus